Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Fornaro

Showing results (1-10 of 76) with videos related to

Pageof 8
Sort By:
Journal of Scleroderma and Related Disorders|June 8, 2023
Subcutaneous immunoglobulin therapy for refractory skin thickening in rapidly progressive systemic sclerosis: A case report and literature reviewFabio Cacciapaglia, Stefano Stano, Marco Fornaro, et al.
Clinical Rheumatology|January 11, 2019
A Bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritisVincenzo Venerito, Giuseppe Lopalco, Fabio Cacciapaglia, et al.
European Journal of Clinical Investigation|July 30, 2020
Predictors of long-term clinical remission in rheumatoid arthritisMarco Fornaro, Fabio Cacciapaglia, Giuseppe Lopalco, et al.
Journal of Personalized Medicine|March 25, 2022
Comparison of Adalimumab to Other Targeted Therapies in Rheumatoid Arthritis: Results from Systematic Literature Review and Meta-AnalysisFabio Cacciapaglia, Vincenzo Venerito, Stefano Stano, et al.
Rheumatology (Oxford, England)|November 22, 2023
Effectiveness of biological targeted therapies may discriminate seronegative from seropositive rheumatoid arthritisFlorenzo Iannone, Giuseppe Lopalco, Fabio Cacciapaglia, et al.
Rheumatology (Oxford, England)|October 26, 2019
Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritisFlorenzo Iannone, Mariangela Nivuori, Marco Fornaro, et al.
European Journal of Clinical Investigation|July 13, 2020
Cardiovascular risk estimation with 5 different algorithms before and after 5 years of bDMARD treatment in rheumatoid arthritisFabio Cacciapaglia, Marco Fornaro, Vincenzo Venerito, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|September 20, 2021
A Machine Learning Approach for Predicting Sustained Remission in Rheumatoid Arthritis Patients on Biologic AgentsVincenzo Venerito, Orazio Angelini, Marco Fornaro, et al.
Reumatismo|April 7, 2025
Real-life effectiveness of rituximab in different subsets of idiopathic inflammatory myopathiesStefano Stano, Fabio Cacciapaglia, Laura Coladonato, et al.
Clinical and Experimental Rheumatology|September 8, 2021
High CD14+ peripheral monocytes expression of ALX/FPR2 and BLT1 in low disease activity and remission status in rheumatoid arthritis: a piltot studySimone Perniola, Rita Bizzoca, Marco Fornaro, et al.
Pageof 8

Showing results (1-10 of 76) with videos related to

Sort By:
Pageof 8
Journal of Scleroderma and Related Disorders|June 8, 2023
Subcutaneous immunoglobulin therapy for refractory skin thickening in rapidly progressive systemic sclerosis: A case report and literature reviewFabio Cacciapaglia, Stefano Stano, Marco Fornaro, et al.
Clinical Rheumatology|January 11, 2019
A Bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritisVincenzo Venerito, Giuseppe Lopalco, Fabio Cacciapaglia, et al.
European Journal of Clinical Investigation|July 30, 2020
Predictors of long-term clinical remission in rheumatoid arthritisMarco Fornaro, Fabio Cacciapaglia, Giuseppe Lopalco, et al.
Journal of Personalized Medicine|March 25, 2022
Comparison of Adalimumab to Other Targeted Therapies in Rheumatoid Arthritis: Results from Systematic Literature Review and Meta-AnalysisFabio Cacciapaglia, Vincenzo Venerito, Stefano Stano, et al.
Rheumatology (Oxford, England)|November 22, 2023
Effectiveness of biological targeted therapies may discriminate seronegative from seropositive rheumatoid arthritisFlorenzo Iannone, Giuseppe Lopalco, Fabio Cacciapaglia, et al.
Rheumatology (Oxford, England)|October 26, 2019
Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritisFlorenzo Iannone, Mariangela Nivuori, Marco Fornaro, et al.
European Journal of Clinical Investigation|July 13, 2020
Cardiovascular risk estimation with 5 different algorithms before and after 5 years of bDMARD treatment in rheumatoid arthritisFabio Cacciapaglia, Marco Fornaro, Vincenzo Venerito, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|September 20, 2021
A Machine Learning Approach for Predicting Sustained Remission in Rheumatoid Arthritis Patients on Biologic AgentsVincenzo Venerito, Orazio Angelini, Marco Fornaro, et al.
Reumatismo|April 7, 2025
Real-life effectiveness of rituximab in different subsets of idiopathic inflammatory myopathiesStefano Stano, Fabio Cacciapaglia, Laura Coladonato, et al.
Clinical and Experimental Rheumatology|September 8, 2021
High CD14+ peripheral monocytes expression of ALX/FPR2 and BLT1 in low disease activity and remission status in rheumatoid arthritis: a piltot studySimone Perniola, Rita Bizzoca, Marco Fornaro, et al.
Pageof 8